HOME >> BIOLOGY >> NEWS
AutovaxID-C introduced by Accentia Biopharmaceuticals

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced that its subsidiary, Biovest International, Inc., presented its newest cell culture instrument, the AutovaxIDTM-C, at the Cancer Research Institute's recent meeting, "Cancer Vaccines: Barriers, Endpoints and Opportunities." This was the first introduction of the AutovaxID-C to the biotech industry.

The AutovaxID-C is an automated hollow fiber cell culture instrument that collects secreted protein from cells and controls the growth of the cells automatically for 30 days or more. Growth takes place in sterile, disposable patient specific modules that are bar coded for ease of tracking and identification. Biovest believes that the AutovaxID-C instrument represents a significant advance in personalized medicine because it reduces the possibility of cross contamination and allows segregation of patient specific vaccine batches. Further expected advantages include reduced manpower requirements, automated batch record generation and improved efficiency in facility design.

"Cancer vaccines are one of the most exciting and promising fields of personalized medicine," said Carl M. Cohen, Ph.D., Chief Operating Officer, Biovest. "The production of a patient specific vaccine to immunize individuals against their own cancers has been a goal of investigators in both academia and industry. Biovest is currently testing an idiotype vaccine to treat follicular non-Hodgkin's lymphomas in a Phase 3 clinical trial."

"Our approach is unique in that it uses hybridoma technology to produce complete idiotype proteins identical to those on the tumor B cells. Results from early clinical trials are very encouraging and generating a lot of excitement in the medical community; however, there has been some concern about the challenge of producing personalized vaccines on a large scale. At this meeting we presented the first of a suite of instruments, designed and produced by the Biovest Advanced Inst
'"/>

Contact: Sherran Brewer
sbrewer@accentia.net
866-481-9020
SciWords
8-Dec-2005


Page: 1 2 3

Related biology news :

1. AutovaxID-C introduced by Biovest International
2. First SCID gene chip to be introduced at Academy meeting on immunodeficiencies
3. Ape computers introduced in the US
4. FDA grants Accentia Biopharmaceuticals...
5. Accentia Biopharmaceuticals announces option agreement with Mayo
6. Accentia Biopharmaceuticals acquires exclusive license
7. Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2018)... ... August 28, 2018 , ... Johanna Dwyer, founder and Chief ... of excellence in the field of intellectual property, and named Daniela Sanchez as ... IP Award aims to encourage and support women in their pursuit of careers ...
(Date:8/26/2018)... ... August 23, 2018 , ... Clinical ... sensitivity and specificity over more commonly used analytical techniques. However, implementation can be ... of development and validation of methods that must be undertaken by the laboratory ...
(Date:8/23/2018)... ... August 21, 2018 , ... Mandy is an eight-year-old mini Australian shepherd and a tripod. ... She went through three surgeries to try to repair the leg and each time ... the leg so her owner, along with her veterinarian, decided to amputate. With only ...
Breaking Biology News(10 mins):
(Date:8/29/2018)... ... August 28, 2018 , ... CEO ... of a safety study performed on an allogeneic (donor derived) stem cell product ... Association (NAVRMA) conference in September. He is also the organizer of Breakout ...
(Date:8/23/2018)... ... August 22, 2018 , ... Crucial Data Solutions, Inc. ... it the first fully-featured app for electronic data capture (EDC) and electronic participant ... constitute 99 percent of the market share for mobile devices worldwide; in turn, ...
(Date:8/17/2018)... ... August 16, 2018 , ... KCAS Bioanalytical and Biomarker Services, ... of their team. Dr. Dawn Dufield, Ph.D., joins KCAS as Director of BioPharma. ... group that will specialize in developing quantitative LC-MS/MS assays for biopharma molecules. Dr. ...
(Date:8/14/2018)... ... 14, 2018 , ... The growing interest in PEEK-OPTIMA™ spinal ... Association of Orthopaedic Surgeons (CAOS) held in partnership with the North American Spine ... and Invibio Biomaterial Solutions partnered to demonstrate the new Uplifter® Expandable ...
Breaking Biology Technology:
Cached News: